Opko was among the investors in genetic disease therapy develoepr Eloxx's series C round, which has now been increased by a further $6m to $30m.
Eloxx Pharmaceuticals, an Israel-based developer of treatments for genetic diseases, has added $6m to a series C round featuring medical diagnostics technology provider Opko Health that now totals $30m.
The round included venture capital firms Korea Investment Partners, Pontifax and DSC Investments, and private investor Phil Frost. It comes ahead of a planned reverse merger by Eloxx with US-based biopharmaceutical company Sevion Therapeutics, where Frost, who is also CEO of Opko, is a board member.
Sevion and Eloxx agreed the acquisition…
